Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the Swiss Association against Osteoporosis (SVGO/ASCO)

Antiosteoporotic drugs are recommended in patients with fragility fractures and in patients considered to be at high fracture risk on the basis of clinical risk factors and/or low bone mineral density. As first-line treatment most patients are started with an antiresorptive treatment, i.e. drugs t...

Full description

Bibliographic Details

Published in:	Swiss Medical Weekly
Main Authors:	Christian Meier, Brigitte Uebelhart, Bérengère Aubry-Rozier, Martin Birkhäuser, Heike A. Bischoff-Ferrari, Diana Frey, Reto W. Kressig, Olivier Lamy, Kurt Lippuner, Petra Stute, Norbert Suhm, Serge Ferrari
Format:	Article
Language:	English
Published:	SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2017-08-01
Subjects:	bisphosphonates denosumab fractures osteoporosis Treatment
Online Access:	https://www.smw.ch/index.php/smw/article/view/2352